News
Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting
Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101
Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101
Celyad to Participate at Upcoming Healthcare Conferences
Celyad to Participate at Upcoming Healthcare Conferences
Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting
Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting
Celyad appoints Carri Duncan as Vice-President Corporate Development & Communications
Celyad appoints Carri Duncan as Vice-President Corporate Development & Communications
Celyad to Participate at Upcoming Healthcare Conferences
Celyad to Participate at Upcoming Healthcare Conferences
Celyad Successfully Doses First Colorectal Cancer Patient with CYAD-01 Following Preconditioning Chemotherapy
Celyad Successfully Doses First Colorectal Cancer Patient with CYAD-01 Following Preconditioning Chemotherapy
Celyad to participate at upcoming healthcare conferences in September
Celyad to participate at upcoming healthcare conferences in September
Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy
Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy
Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018
Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018
Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient
Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient
Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018
Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018